ARDELYX, INC. Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
ARDELYX, INC. (ARDX) had Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One of $44.27 million as of 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Notes › Investments › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost · last filed 2022-02-28
- 2021-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $44.27M.
- 2020-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $95.45M.
| Period end | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2021-12-31 | $44.27M 10-K · filed 2022-02-28 |
| 2020-12-31 | $95.45M 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |